Meridian Bioscience Receives Re-Authorization from FDA For Its Revogene SARS-CoV-2 Molecular Assay
Author: Benzinga Newsdesk | July 29, 2022 09:24am
Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received re-authorization of its Emergency Use Authorization (EUA) for the Revogene® SARS-COV-2 molecular assay from the U.S. Food and Drug Administration (FDA). Meridian expects to begin shipping this product before the end of its fiscal fourth quarter, ending September 30, 2022.
Posted In: VIVO